Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Vir Biotechnology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vir Biotechnology's operating cash flow for the twelve months ending Jun 30, 2026 was -$202.51M. For fiscal 2025 it was -$391.78M. The highest annual figure on record is $1.66B in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$391.78M | – |
| FY2024 | Dec 31, 2024 | -$446.35M | – |
| FY2023 | Dec 31, 2023 | -$778.79M | -146.8% |
| FY2022 | Dec 31, 2022 | $1.66B | – |
| FY2021 | Dec 31, 2021 | -$47.59M | – |
| FY2020 | Dec 31, 2020 | -$190.94M | – |
| FY2019 | Dec 31, 2019 | -$129.63M | – |
| FY2018 | Dec 31, 2018 | -$94.10M | – |
| FY2017 | Dec 31, 2017 | -$66.38M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $123.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$132.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$167.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$120.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$78.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$87.64M | – |
| Q3 FY2024 | Sep 30, 2024 | -$171.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$77.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$109.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$107.93M | -407.3% |
| Q3 FY2023 | Sep 30, 2023 | -$155.83M | -232.2% |
| Q2 FY2023 | Jun 30, 2023 | -$389.25M | -140.5% |
| Q1 FY2023 | Mar 31, 2023 | -$125.78M | -122.9% |
| Q4 FY2022 | Dec 31, 2022 | $35.13M | +356.5% |
| Q3 FY2022 | Sep 30, 2022 | $117.90M | – |
| Q2 FY2022 | Jun 30, 2022 | $960.14M | +585.5% |
| Q1 FY2022 | Mar 31, 2022 | $550.09M | – |
| Q4 FY2021 | Dec 31, 2021 | $7.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$105.81M | – |
| Q2 FY2021 | Jun 30, 2021 | $140.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$89.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$82.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$49.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$48.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$38.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$36.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.30M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$29.51M | – |
See a number that looks wrong?